Friday, August 16, 2013

FAQ’s & FREQUENT QUESTIONS ABOUT I.P.T. PART 1


LEARN THE FACTS AND MOST FREQUENT QUESTIONS ABOUT I.P.T.

I.     What is IPT?
II.    How does it work?
III.  Scientific explanation
IV.  Who administers these treatments?
V.    What types of cancer does IPT treat?


I.

IPT stands for Insulin Potentiation Therapy, discovered by Dr. Donato Perez Garcia in Mexico City, 1930. It is a patented medical protocol used to treat cancer with less dosage of chemotherapy, using insulin as a natural potentiator that targets only cancer cells, reducing chemotherapy’s toxic side effects, adding natural and biologic medicine to help restore the body’s natural defenses. It has been developed and researched for over 80 years; today it is administered by the grandson of the founder, also named Donato Perez Garcia, M.D.
IPT, subsequently developed in Insulin Potentiation Targeted Low Dose (IPTLD), is a treatment that has cured cancer patients, of all types and stages, around the world. There are more than 451 doctors practicing this protocol in more than 31 countries worldwide.

II.

Let’s define cancer as a loss of harmony and complete disorder of normal physical and chemical functioning in the body, activated by a cancer genic agent.
It all starts with insulin; a hormone produced in the pancreas that regulates metabolism of carbohydrates, fat and excess glucose from the blood. But it has many more functions on a cellular level. With a single shot, Insulin Potentiation Therapy uses insulin to modify cancer cells molecular biology, inducing a controlled state of hypoglycemia. And because a cancer cells contains 10 times more insulin receptors than healthy cells, insulin can help target the medication only to cancer cells. Once it has reached them, insulin promotes the permeabilization of the cell’s membrane. Only a trained IPT medical physician will know the exact timing when this happens, also known as “The Therapeutic Moment”, that’s when all chemotherapy drugs are administered thru I.V. in far less amounts into the patient. Insulin Potentiation Targeted Therapy changes the   bio-physic-chemical constants and parameters of the blood, attacking first the cancerous cell through its intra-extra cellular environment, permeabilizing the cell’s membrane. This permeabilization assures that anticancer medication will effectively enter the damaged cells and eventually kill them, reducing the affected cancer tissue.

The administration of chemo is so effective that IPT only uses less than half the dosage of what you’d receive in a traditional chemotherapy session. This will dramatically reduce your level of toxicity (cause by chemotherapy’s strong medication), with hardly any side effects, giving you more energy and vitality to fight the disease and live a healthy life.

As part of an IPT treatment, you will also receive a detoxification protocol of biologic medicine, essential nutrients and immune boosters that will fortified your white cells, helping your own body defend itself against any cancer agent. Healthy cells remain intact, thus promoting a better quality of life, while fighting the disease. It is a potent, effective treatment for cancer, in a gentler, kinder way that wont damage or exert your body. It is the next generation for administering chemotherapy.

III.

Insulin Potentiation Therapy + Targeted Low Dose (IPTLD ®) manipulates the mechanisms of malignancy to therapeutic advantage by employing insulin as a biologic response modifier of cancer cells endogenous molecular biology. The autonomous proliferation of malignancy is supported by autocrine secretion of insulin for glucose/energy uptake by cancer cells, and a similar autocrine and/or paracrine elaboration of cellular factors to stimulate cancer growth. Amongst these, the insulin-like growth factors have been identified as the most potent mitogens for cancer cells.

Of primary importance for IPTLD ®, cancer cell membranes also have six times more insulin receptors and ten times more IGF receptors, per cell, than the membranes of host normal tissues. Further, insulin can cross-react with and activate cancer cell IGF receptors. Thus, per cell, cancer has sixteen times more insulin-sensitive receptors than normal tissues. As ligand effect is a function of receptor concentration, these facts serve to differentiate cancer from normal cells - a vital consideration for the safety of cancer chemotherapy. In light of these revelations, exogenous insulin acts to enhance anticancer drug cytotoxicity, and safety, via:

1) A membrane permeability effect to increase the intracellular dose intensity of the drugs;
2) An effect of metabolic modification to increase the S-phase fraction in cancer cells, enhancing their susceptibility to cell-cycle phase-specific agents, and;
3) An effect of biochemical differentiation based on insulin receptor concentration that focuses the first two insulin effects predominantly on cancer cells, sparing host normal tissues.

Significantly fewer drugs can thus be targeted more specifically and more effectively to cancer cell populations that are more susceptible to the chemotherapy drug effects, all this occurring with a virtual elimination of the dose-related side effects of these powerful drugs.

Because of this favorable decrease of side effects, cycles of low-dose chemotherapy with IPTLD ® may be done more frequently. There is good patient acceptance of the hypoglycemic side effect of insulin in this protocol, and the "rescue phenomenon" occasioned by the timely administration of hypertonic glucose actually serves to provide patients with an experiential metaphor for the rapid recovery of their well being. It is acknowledged that cancer treatment can often be debilitating for patients. In those undergoing treatment with IPTLD ®, an overall gentler experience promotes their concurrent use of other important elements in a program of Comprehensive Cancer Care.

IV.

The most experienced IPT Medical Doctor is Donato Perez Garcia. He is the 3rd generation of IPT physicians, all of the same name. In 1982 he began working with his father, Donato Pérez García Bellón, where he learned the therapy discovered by his grandfather. Together they attended several conferences within the Mexican republic, then the United States and Europe.
In February of 2001, he conducted the first IPT training seminar in the city of Las Vegas, where 21 doctors from the United States and Canada attended. During the following years he dedicated himself in introducing the treatment in Mexico, South America, Europe, Asia and North Africa, training physicians that offer IPT as an option for treating cancer and other degenerative diseases. Since then, he’s continued with annual seminars, attended by international doctors and presentations on IPTLD® to the United States government organization NIH/NCI/OCCAM.

In 2002 he held the first IPT Non-Profit Congress, where physicians could exchange scientific knowledge. Few years ago, he was invited to open an office in the Medical Consultation Tower in Hospital Angeles de Tijuana. During this period he started making changes to the treatment administration protocol, now formally called Insulin Potentiation Targeted Low Dose (IPTLD). He currently practices medicine in Hospital Angeles in Tijuana, Baja California, Mexico. On January of 2013 he was promoted for a three-year period as Medical Advisory in Research for the Health Committee of LXII Legislature. Chamber of Deputies. United States of Mexico. Government of Mexico.

Has over 30 years experience in IPT. Has applied over 26,000 treatments to patients worldwide.

V.

The most common are:

* Breast
* Lung
* Ovarian
* Uterine
* Prostate
* Bone
* Lymphoma
* Cervix
* Melanoma
* Renal Cell
* Fibro sarcoma
* Hodgkin's
* Leukemia

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.